Rheumatoid Arthritis Drugs Market Overview:
The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.
Rheumatoid arthritis is a disease that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly susceptible to develop this disease. The symptoms of rheumatoid arthritis include pain, stiffness, tender, and swelling of joints. Currently, no cure is available for rheumatoid arthritis. However, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.
Rise in prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drugs, expiration of patents & the entry of biosimilar drugs, surge in geriatric population, increase in adoption of conventional DMARDs, and government initiatives toward spread in awareness for rheumatoid arthritis symptoms are the major factors that drive growth of the rheumatoid arthritis drugs market. In addition, innovations in advanced biologics, rise in healthcare expenditure, improvement in buying power, and access to quality drugs to poor & middle-class families globally are some other factors that contribute toward growth of the market. However, side effects associated with the medication and high costs of biological DMARD therapies are expected to act as the key restraints of the global market. On the contrary, rise in awareness related to early screening and treatment of rheumatoid arthritis is anticipated to offer high growth potential for the rheumatoid arthritis drugs market during the forecast period.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. According to the Lancet Rheumatology 2020, patients with rheumatoid arthritis who develop COVID-19 infection may be at high risk for developing severe symptoms and additional complications. Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drug, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs during the forecast period.
Rheumatoid Arthritis Drugs Market Segmentation
The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Drug Class
Disease-modifying Anti-rheumatic Drugs segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
Segment review
Presently, on the basis of drug class, the disease-modifying anti-rheumatic drugs (DMARDs) is the major revenue contributor, and is projected to grow significantly during the forecast period. Rise in awareness related to the use of DMARDs, surge in prevalence of rheumatoid arthritis, rise in obese & overweight population across the globe, and increase in adoption of DMARDs as a first-line treatment for rheumatoid arthritis are the key factors that boost growth of the segment.
Depending on sales channel, the prescription-based drugs segment is the major shareholder in the global rheumatoid arthritis drugs market, owing to advantages offered by prescription-based drugs such as patients gets the correct dosage of the drug during the treatment of rheumatoid arthritis, without causing any side effects, and it prevents the potential scope of drug misuse. However, the OTC drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to convenience of direct purchase and increase in innovations & developments in OTC drugs.
By Sales Channel
Prescription-Based Drugs segment is projected as one of the most lucrative segment.
Snapshot of Asia-Pacific rheumatoid arthritis drugs market
Asia-Pacific presents lucrative opportunities for key players operating in the rheumatoid arthritis drugs market, owing to the presence of large population base susceptible to rheumatoid arthritis, increase in public awareness toward use & benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in adoption of rheumatoid arthritis drugs. Moreover, increase in demand for DMARDs and rise in geriatric population contribute toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high rheumatoid arthritis drugs market share is expected to drive growth of the market in the region.
The key players profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A.
By Region
Asia-Pacific region would exhibit the highest CAGR of 3.2% during 2019-2026.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the rheumatoid arthritis drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers rheumatoid arthritis drugs market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the rheumatoid arthritis drugs market.
- A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global rheumatoid arthritis drugs market growth.
Rheumatoid Arthritis Drugs Market Report Highlights
| Aspects | Details |
 By Drug Class Type |
|
 By Route Of Administration |
|
 By Sales Channel |
|
 By Region |
|
 Key Market Players | F. HOFFMANN-LA ROCHE LTD., PFIZER INC., AMGEN INC., NOVARTIS AG (SANDOZ), BRISTOL-MYERS SQUIBB COMPANY, MERCK & CO., INC., JOHNSON & JOHNSON, UCB S.A., ELI LILLY AND COMPANY, ABBVIE INC. |
Analyst Review
Rheumatoid arthritis is a chronic inflammatory medical disease in which the body’s immune system attacks its own tissue such as joints. This leads to painful swelling and stiffness in the joints. The medications used for the treatment of rheumatoid arthritis are called anti-rheumatic drugs.
The utilization of rheumatoid arthritis drugs has witnessed a significant growth, owing to surge in incidences of rheumatoid arthritis. The other factors that propel the utilization of different rheumatoid arthritis drugs include increase in geriatric population across the globe, as the medical condition is more predisposed in elderly patients. Conversely, high price of the biological DMARD is a major factor that hinders the growth of the market. Whereas, surge in awareness related to the use of rheumatoid arthritis drugs is expected to present lucrative opportunities for the key players during the forecast period.
North America is expected to remain dominant during the forecast period, due to increase in demand for rheumatoid arthritis drugs, alarming rise in prevalence of rheumatoid arthritis, and presence of major key players along with R&D centers. Moreover, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to increase in patient awareness toward rheumatoid arthritis treatment.
The total market value of Rheumatoid Arthritis Drugs market is $57,928.5 million in 2019.
The forcast period for Rheumatoid Arthritis Drugs market is 2020 to 2027
The market value of Rheumatoid Arthritis Drugs market in 2020 is $52,048.8 million.
The base year is 2019 in Rheumatoid Arthritis Drugs market
Top companies such as AbbVie Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, and UCB S.A. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Disease-modifying anti-rheumatic drugs segment is the most influencing segment owing to rise in prevalence of rheumatoid arthritis syndrome across the globe, increase in obese & overweight population, launch of therapeutic agents, and favorable reimbursement policies for high cost treatments
Rise in incidence of rheumatoid arthritis, increase in demand for DMARDs, and surge in geriatric population across the globe are the key factors that fuel the growth of the global rheumatoid arthritis drugs market. In addition, rise in patient awareness toward availability of various treatments for rheumatoid arthritis, increase in focus of pharmaceutical companies to tap the rare & specialty diseases, and rise in R&D activities and product innovations notably contribute toward the growth of the global market
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 3.9%. This is due to increase in geriatric population, increase in healthcare expenditure and surge in awareness related to the use of rheumatoid arthritis drugs, surge in prevalence of rheumatoid arthritis, surge in adoption of disease-modifying DMARDs, and improvement in healthcare infrastructure.
Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs. It is considered as a systemic disease, as it affects the cardiac and respiratory system
Rheumatoid arthritis drugs are used to reduce or prevent joint damage associated with inflammatory conditions of the joints
Loading Table Of Content...
